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To estimate the net effect of imperfectly measured highly active antiretroviral therapy on incident acquired
immunodeficiency syndrome or death, the authors combined inverse probability-of-treatment-and-censoring
weighted estimation of a marginal structural Cox model with regression-calibration methods. Between 1995 and
2007, 950 human immunodeficiency virus–positive men and women were followed in 2 US cohort studies. During
4,054 person-years, 374 initiated highly active antiretroviral therapy, 211 developed acquired immunodeficiency
syndrome or died, and 173 dropped out. Accounting for measured confounders and determinants of dropout, the
weighted hazard ratio for acquired immunodeficiency syndrome or death comparing use of highly active antiretroviral
therapy in the prior 2 years with no therapy was 0.36 (95% confidence limits: 0.21, 0.61). This association was
relatively constant over follow-up (P ¼ 0.19) and stronger than crude or adjusted hazard ratios of 0.75 and 0.95,
respectively. Accounting for measurement error in reported exposure using external validation data on 331 men and
women provided a hazard ratio of 0.17, with bias shifted from the hazard ratio to the estimate of precision as seen by
the 2.5-fold wider confidence limits (95% confidence limits: 0.06, 0.43). Marginal structural measurement-error
models can simultaneously account for 3 major sources of bias in epidemiologic research: validated exposure
measurement error, measured selection bias, and measured time-fixed and time-varying confounding.
acquired immunodeficiency syndrome; bias (epidemiology); cohort studies; confounding factors (epidemiology);
epidemiologic measurements; HIV; pharmacoepidemiology; selection bias
Abbreviations: AIDS, acquired immunodeficiency syndrome; CL, confidence limits; HAART, highly active antiretroviral therapy;
HIV, human immunodeficiency virus; IPTC, inverse probability of treatment and censoring; MACS, Multicenter AIDS Cohort Study;
SE, standard error.
Incident acquired immunodeficiency syndrome (AIDS)
is a central clinical event in the progression of human
immunodeficiency virus (HIV) infection. Because of a dem-
onstrated (1–3) strong, immediate protective effect of highly
active antiretroviral therapy (HAART), randomized evidence
bearing on the long-term effectiveness of HAART remains
unavailable.
Observational analyses of prospective cohorts to estimate
the effectiveness of HAART are difficult because one must
measure and account for known and unknown time-fixed
and time-varying confounders (4, 5). Standard adjustment
or stratification for known time-varying confounders fails to
consistently estimate the net (i.e., direct and indirect) effect
of HAART on incident AIDS (6) and allows possible selec-
tion bias (7–9). Prior observational analyses accounting for
known time-varying confounders (10, 11) have 1) assumed
once initiated on HAART, individuals continue to use ther-
apies (10, 11); 2) taken reported HAART use as measured
without error (10); 3) followed participants for 6.5 years
(10) to 7.5 years (11); and 4) estimated discrepant effects
of HAART (hazard ratios ranged from 0.14 (11) to
0.54 (10)), depending in part on the specification of the
comparison group.
In the present paper, we use data from ongoing observa-
tional cohort studies of adult women and men to estimate
the net effect of HAART use, versus no antiretroviral
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therapy use, on AIDS-free survival over a period of more
than 11 years. We allow individuals to start and stop therapy
at each semiannual study visit and correct for exposure
measurement error in reported HAART use based on pooled
external validation data. We combine use of inverse
probability-of-treatment-and-censoring (IPTC) weighted
estimation of a marginal structural Cox model (12, 13) with
regression calibration (14–17), which together enable
consistent estimation of the net effect of HAART exposure
under the assumptions of no unmeasured confounding, no
informative censoring, no residual measurement error, and




This analysis used information from theMulticenter AIDS
Cohort Study (MACS) (18), which beginning in 1984
enrolled 6,972 homosexual and bisexual men in Baltimore,
Maryland; Chicago, Illinois; Pittsburgh, Pennsylvania; and
Los Angeles, California, and from the Women’s Interagency
HIV Study (19), which beginning in 1994 enrolled 3,772
women in New York, New York; Chicago; Los Angeles;
San Francisco, California; and Washington, DC. Every 6
months, participants in both studies completed a physical
examination and an extensive interviewer-administered
questionnaire with information on antiretroviral therapy
use and provided a blood sample for the determination of
CD4 cell count and HIV-1 viral load. Positive enzyme-linked
immunoabsorbent assays with confirmatory Western blots
were used to determine HIV-1 seropositivity. Institutional
review boards approved all protocols and informed consent
forms, which were completed by study participants in both
cohorts.
Analyses presented here include the 950 men and women
who were alive, HIV seropositive, and not using antiretro-
viral therapies in April 1995 before HAART became
available (first regimen approved by the US Food and Drug
Administration on December 6, 1995). Each participant
contributed a maximum of 24 study visits beginning with
the first semiannual visit after April 1995 (the baseline visit)
and ending with the last visit that he or she was seen alive
without clinical AIDS, before initiation of non-HAART
antiretroviral therapy, at the second consecutive missed visit
(i.e., dropout), or at the date of analysis in September 2007,
whichever occurred first. For participants missing baseline
data on any time-varying covariate, baseline was redefined
to be the first visit with complete data. This approach is
analogous to late entries in survival analysis (20) and as-
sumes that late entry is noninformative (21).
AIDS and death ascertainment
The endpoints of interest were first diagnosis of clinical
AIDS or death from any cause. The 1993 Centers for Dis-
ease Control and Prevention clinical conditions criteria were
used to define clinical AIDS (22). Therefore, participants
were not considered to have clinical AIDS if they had only
a CD4 count of <200 cells/mm3 or a CD4 percentage of
<14 but no clinical AIDS-defining condition. A description
of outcomes ascertainment has been published elsewhere
(18, 23). Briefly, physician or hospital records confirmed
reported clinical AIDS cases among the cohort of men,
whereas the cohort of women self-reported clinical AIDS.
Deaths were ascertained by using death certificate abstrac-
tions upon notification and National Death Registry
searches.
Assessment of HAART
The primary exposure was use of HAART in the prior
2 years versus no antiretroviral therapy, because this com-
parison is of current clinical interest (11). We also explored
recent and long-term HAART use (as defined below). The
definition of HAART was based on the US Department of
Health and Human Services panel guidelines (24), as
previously published (10). Typical HAART regimens con-
sisted of 2 or more nucleoside or nucleotide reverse tran-
scriptase inhibitors in combination with 1 or more protease
inhibitor or 1 nonnucleoside reverse transcriptase inhibitor.
Assessment of covariates
A number of time-fixed and time-varying covariates were
recorded. T-lymphocyte subsets were determined by immu-
nofluorescence using flow cytometry (Becton Dickinson,
Mountain View, California) (25). The HIV-1 RNA viral
load, in copies per milliliter of plasma, was measured
by using an isothermal nucleic acid sequence-based ampli-
fication method for women (bioMérieux, Boxtel, the
Netherlands) and a reverse transcription polymerase chain
reaction amplification assay for men (Roche Molecular
Systems, Branchburg, New Jersey). Missing time-varying
covariate information after the baseline visit (9%) was
carried forward from the most recent prior observed value.
Statistical methods
Let uppercase letters denote random variables and lower-
case letters possible realizations. Let Yij ¼ 1 indicate incident
AIDS or death during the visit interval (j, jþ 1], 0 otherwise,
for participant i ¼ 1 to N and visit j ¼ 0 to Ji  1. Let Ji be
the minimum of the last study visit or the (planned) visit
subsequent to incident AIDS, death, or censoring. There-
fore, the timescale is time on study. Let Cij ¼ 1 indicate
dropout or initiation of non-HAART therapy during the
visit interval (j, j þ 1], 0 otherwise. Let Xij ¼ 1 indicate
reported use of HAART in the visit interval ( j  1, j],
0 otherwise. Let Zij ¼ 1 indicate actual use of HAART
in the same visit interval. Finally, let Lij denote time-
varying covariates measured at visit j. Denote the history
of a time-varying variable using overbars, so that
X ¼ Xij ¼

Xi0;Xi1; . . . ;Xij

is the history of exposure to
HAART through visit j.
A marginal structural (12) pooled logistic regression (26)
model is
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log
(
PrðY x;c¼0ij ¼ 1Þ
1 PrðY x;c¼0ij ¼ 1Þ
)
¼ b0j þ b1gðxÞ;
where Y x;c¼0ij is a time-varying indicator of incident AIDS
or death in the visit interval ðj; jþ 1 if the participant
had followed treatment history x; c ¼ 0, and
gðxÞ ¼ minð4; jþ 1Þ1
Pj
k¼maxð0;j3Þ xik is the proportion
of reported HAART use over the prior 4 study visits.
Our estimand is a discrete-time hazard ratio for incident
AIDS or death, expðb1Þ, comparing treatment with
HAART over the prior 4 visits (approximately 2 years)
against no antiretroviral therapy. We also considered re-
cent exposure, gðxÞ ¼ xij, and exposure over the entire
follow-up period, gðxÞ ¼ j1
Pj
k¼0 xik.































, Ŵij are esti-
mated time-varying IPTC weights (described below) and b0j
are visit-specific intercepts fit by using a restricted cubic
spline with 4 knots at the 5th, 33rd, 67th, and 95th percen-
tiles. The discrete-time hazard ratio well approximates the
continuous time hazard ratio when the risk of AIDS or
death in any interval is less than 10%, which held in our
example because the largest event proportion in any visit
interval was 6%.
To account for time-varying confounding of HAART use
and for right censoring by dropout or non-HAART antiret-
roviral therapy initiation, we fit the above pooled logistic
model using stabilized IPTC weights of the form




f ½Xikj Xik1; Cik1 ¼ 0





Pr½Cik ¼ 0j Cik1 ¼ 0; Xik
=Pr½Cik ¼ 0j Cik1 ¼ 0; Xik; Lik1 ;
where f ½j is the conditional density function evaluated at
the observed covariate values for a given participant.
Baseline covariates Li0 were measured at the semiannual
study visit immediately prior to the baseline visit and
included age, sex, CD4 count categories (i.e., <200, 200–
350, 351–500, >500 cells/mm3), and viral load categories
(i.e., <4,001, 4,001–10,000, and >10,000 copies/mL). The
IPTC weights were stabilized by past HAART exposure,
namely fXik1, Xik2, Xik3g, to represent Xik1. The
time-varying covariate histories Lik1 were specified as re-
stricted cubic splines (with 4 knots located at the same
percentiles as given above) for CD4 cell count and log10
HIV viral load both measured at visit k  1. We estimated
the components of Wij using pooled logistic regression
models, as previously described (27). If confounding by
unmeasured factors is absent and censoring is ignorable,
the IPTC weighted estimates b of the pooled logistic model
approximate the parameters b of the marginal structural
model. Formal definitions of unmeasured confounding and
ignorable censoring are given in Hernán et al. (13).
Regression calibration (14–17) using external validation
data was applied to the IPTC weighted data. In the weighted
data, the relation of the measured confounders Lij1 and the
misclassified exposure Xij is removed, but the relation
between the misclassified Xij and true exposure Zij persists
(28). Therefore, given a mapping (i.e., calibration) of the
relation between the misclassified Xij and true exposure Zij
in the nonconfounded weighted data, one is able to correct
for misclassification of exposure by using regression
calibration. Details of the validation data, which include
studies of 126 MACS men and 205 patients enrolled in
the University of North Carolina Center for AIDS Research
clinic cohort, are provided in Appendix 1; details of regres-
sion calibration are given in Appendix 2. A limited Monte
Carlo simulation demonstrating some finite sample proper-
ties of the proposed approach is provided in Appendix 3.
On the basis of prior research (10, 27, 29), interactions
between HAARTand sex and between HAARTand baseline
CD4 cell count categories were explored. We also explored
the constancy of the hazard ratio over time on study using
both a product between treatment and (continuous) time and
a split at 2 years, which is approximately the median event
time. To explore the variance traded to account for possible
bias due to time-varying confounding, we truncated the
IPTC weights from below and above at percentiles 1 and
99, respectively (30). In addition to marginal structural
models, we fit standard pooled logistic regression models
with the same time-varying exposure and covariates for
comparison, as described previously (10). All analyses were
conducted with SAS version 9 software (SAS Institute, Inc.,
Cary, North Carolina), using robust variance estimates (31)
to calculate confidence limits and P values for the marginal
structural models (refer to the Appendix in Cole et al. (27)).
RESULTS
At study entry, the 950 participants were a median age of
38 (quartiles: 33, 44) years and had a CD4 count of 453
(quartiles: 303, 641) cells/mm3 and a viral load of 4.5
(quartiles: 4, 4.9) log10 copies/mL for the 73% with detect-
able values. Sixty-one percent were women, and 41% were
Caucasian (Table 1).
The 950 participants contributed 4,054 person-years un-
der observation. The median length of follow-up was 2.2
(quartiles: 0.5, 8.6) years over the follow-up period between
September 1995 and September 2007. The CD4 count
averaged over follow-up was 40 cells/mm3 higher and the
HIV viral load was 0.4 log10 copies/mL lower than at base-
line. Two hundred eleven (22%) participants developed
AIDS (n ¼ 180) or died (n ¼ 31) during follow-up,
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307 (32%) completed follow-up alive, 259 (27%) were cen-
sored because of initiation of non-HAART antiretroviral
therapy, and the remaining 173 (18%) were censored
because of study dropout.
Among the 950 participants, 374 (39%) initiated HAART
during follow-up. Two thousand ten of 4,054 person-years
(50%) were contributed prior to HAART exposure, 1,773
person-years (44%) were contributed while participants were
exposed to HAART, and 270 person-years were contributed
by participants following discontinuation of HAART.
Concerning person-years of exposure to HAART, 2,098 of
4,054 person-years (52%) were fully unexposed in the prior
2 years and 1,151 of 4,054 person-years (28%) were fully
exposed; the remaining 20% of 4,054 person-years were
partially exposed in the prior 2 years (i.e., 275, 244, and
286 person-years were attributed to 25%, 50%, and 75%
HAART exposure, respectively). The predicted probability
of HAART use since the prior visit conditional on measured
covariates ranged from 1.1 3 108 to 0.99, with a mean
of 0.40. After stabilization, the IPTC weights ranged from
0.15 to 23.6, with a mean of 0.97; the 1st and 99th percentiles
were 0.28 and 2.87, and quartiles were 0.68, 0.90, and 1.08,
respectively. As expected, for participants not using HAART
at the prior visit, the odds of HAARTuse increased by a factor
of 1.34 (95% confidence limits (CL): 1.28, 1.41) for each
decrement of 100 CD4 cells/mm3 and by a factor of 1.40
(95% CL: 1.07, 1.83) for a detectable viral load.
The unadjusted hazard of AIDS or death was 0.75 (95%
CL: 0.49, 1.17) for those using HAART during the prior
2 years relative to those not using antiretroviral therapy
(Table 2). The adjusted hazard ratio was 0.95 (95% CL:
0.58, 1.56), so the unadjusted hazard ratio of 0.75 was
1.27 times weaker after adjustment for time-varying CD4
cell count and viral load. The adjusted estimate was slightly
less precise, with a 1.14-times larger standard error (for the
log of the hazard ratio, 0.25 vs. 0.22).
The hazard of AIDS or death from the marginal structural
model (i.e., weighted) was 0.36 (95% CL: 0.21, 0.61) for
HAART use in the prior 2 years relative to not using therapy
(Table 2). This weighted estimate was 1.8 and 2.6 times
stronger than the unadjusted and adjusted estimates, respec-
tively. However, the weighted estimate was less precise than
the unadjusted estimate, with a 1.2-times larger standard
error (for the log of the hazard ratio, 0.27 vs. 0.22).
Truncating the IPTC weights at the 1st and 99th percentiles
yielded a similar estimate (hazard ratio ¼ 0.42, 95% CL:
0.26, 0.67) and precision (a 0.89-times smaller standard
error for the log of the hazard ratio, 0.24 vs. 0.27). The effect
of recent HAART use (prior 6 months) and use over the
entire follow-up period, rather than use in the prior 2 years,
yielded weighted hazard ratios of 0.43 (95% CL: 0.28, 0.67)
and 0.25 (95% CL: 0.13, 0.48), respectively.
The effect of HAART during the prior 2 years appeared
stronger among men (hazard ratio ¼ 0.31, 95% CL: 0.13,
0.75) than women (hazard ratio ¼ 0.64, 95% CL: 0.35,
1.20), but this difference may have been due to chance
(P homogeneity ¼ 0.16). The effect of HAART appeared
stronger at lower levels of baseline CD4 count (hazard ratios
Table 1. Baseline and Follow-up Characteristics of 950 Men and Women Infected With HIV
Type 1, Multicenter AIDS Cohort Study and Women’s Interagency HIV Study, 1995–2007
Characteristic
Baseline (1995)
(n 5 950 Persons)
Follow up (1995–2007)
(n 5 9,172 Person-Visitsa)
% Mean (SD) No. % Mean (SD) No.
Age, years 39 (8) 47 (9)
Female sex 61 578 53 4,825
African American 59 560 53 4,839
Use of HAART 0 0 39 3,556
Category of CD4 cell count
(no. of cells/mm3)
<200 11 109 9 793
200–350 21 195 20 1,793
351–500 26 251 24 2,234
>500 42 395 47 4,352
CD4 cell count (no. of cells/mm3) 498 (279) 538 (299)
Category of HIV-1 RNA level
(no. of copies/mL)
<4,001 34 324 58 5,378
4,001–10,000 13 120 11 985
>10,000 53 506 31 2,809
Log10 HIV-1 RNA level (no. of
copies/mL)
4.5 (0.7)b 4.1 (0.7)b
Abbreviations: AIDS, acquired immunodeficiency syndrome; HAART, highly active antiretrovi-
ral therapy; HIV, human immunodeficiency virus; SD, standard deviation.
a 950 people contributed 9,172 person-visits, with 4,054 person-years of follow-up.
b Among 691 and 5,040 detectable measurements at baseline and follow-up, respectively.
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for <200, 200–350, 351–500, and >500 cells/mm3 at
baseline were 0.11, 0.24, 0.40, and 0.47, respectively; P
homogeneity¼ 0.12). The effect of HAARTappeared stron-
ger at earlier time on study, with hazard ratios of 0.14 (95%
CL: 0.03, 0.54) before 2 years and 0.40 (95% CL:
0.23, 0.69) after 2 years from study entry, but this difference
may have been due to chance (P homogeneity ¼ 0.12).
Moreover, a test of the proportional hazards assumption
not categorizing time yielded P homogeneity ¼ 0.19.
When the pooled external validation data were used, the
estimated calibration slope, ĉ1, was 0.57 (95% CL:
0.49, 0.65). In the pooled external validation data, the
percentage of participants using HAART according to med-
ical records, given no reported use, was 35% (standard error
(SE), 5) and the percentage using HAART according to
medical records, given reported use, was 92% (SE, 2).
The hazard of AIDS or death from regression calibration
of the marginal structural model (i.e., weighted and cali-
brated) was 0.17 (¼ exp½lnð0:36Þ=0:57, 95% CL: 0.06,
0.43) for HAART use during the prior 2 years relative to
not using therapy (Table 2). This calibrated estimate was
2.1 times stronger than the weighted estimate. The weighted
and calibrated estimate was less precise than the weighted
estimate, with a 1.8-times larger standard error (for the log
of the hazard ratio, 0.48 vs. 0.27). When we restricted the
external validation data to MACS (hazard ratio ¼ 0.29,
95% CL: 0.15, 0.55) or University of North Carolina (hazard
ratio ¼ 0.12, 95% CL: 0.04, 0.39) as a sensitivity analysis,
results that bounded the estimate using combined data were in
concordance with expectations given the characteristics of the
validation data and provided a range within which the true
result likely resides.
DISCUSSION
Using a marginal structural Cox proportional hazards
model and regression calibration, we estimated that, relative
to not using antiretroviral therapy, HAART use during the
prior 2 years decreases the hazard of AIDS or death by 83%
(range of the 95% CL across sensitivity analysis: 45, 96),
and this effect appears to persist for more than 10 years. This
dramatic protective effect was attenuated by half when
efforts were not made to account for misclassification of
reported HAART use. Moreover, the protective effect was
further attenuated when standard statistical methods were
used to account for the time-varying confounding.
Our results show a stronger effect of HAART on disease
progression than the results reported by the trials described
by Hammer et al. in 1997 (1) and Cameron et al. in 1998
(3) comparing an early HAART regimen with a combination-
therapy regimen. We would expect to see stronger effects
than these trials demonstrated because 1) our comparison
group reflected the absence of antiretroviral therapy rather
than a combination therapy; 2) the HAART regimens used
over the course of follow-up have improved, whereas both
trials used single, early HAART regimens; and 3) both trials
reported noncompliance with assigned therapies, the
magnitude of which could notably null-bias the intent-to-treat
trial results (32–34).
Our results are also stronger than the findings of Detels
et al. (35), who used calendar period as an instrumental
variable (36) for HAARTexposure in a subset of 536 MACS
men for whom seroconversion dates were known and
reported a hazard ratio for incident AIDS or death of
0.35 (95% CL: 0.20, 0.61) in a comparison of the time
period following HAART introduction with the time period
of monotherapy. We would expect to find stronger effects
than Detels et al. (35) because, akin to noncompliance in
a trial, use of calendar period as an instrument for therapies
is subject to information bias if the use of therapies is not
a step function across the calendar periods, which it is not,
as shown in Figure 1 of Detels et al. and in Cain et al. (37).
Indeed, an instrumental variable correction for misclassifi-
cation of the Detels et al. result yielded a rate ratio of
0.2 (38), which is close to our estimate.
Finally, prior observational analyses accounting for time-
varying confounding using marginal structural models
(10, 11) have assumed that, once initiating HAART, indi-
viduals continue to use therapies (10, 11); have taken
reported HAART use as measured without error (10); and
have estimated the effect of HAART versus no therapy
(hazard ratio ¼ 0.14, 95% CL: 0.07, 0.29) (11), mono- or
combination therapy (hazard ratio ¼ 0.51, 95% CL: 0.29,
0.87) (10), combination therapy alone (hazard ratio ¼ 0.49,
95% CL: 0.31, 0.79) (11), or any non-HAART therapy, in-
cluding no therapy (hazard ratio ¼ 0.54, 95% CL: 0.38,
0.78) (10). As expected, the exposure-misclassification-
corrected hazard ratio of 0.17 (95% CL: 0.06, 0.43)
presented here coheres better with a previously reported
hazard ratio of 0.14 (95% CL: 0.07, 0.29), where marginal
structural models were applied to data with HAART
use obtained by medical records (11), than the estimate
assuming no misclassification of reported HAART use
(i.e., 0.36, 95% CL: 0.21, 0.61).
Past work using marginal structural models has largely
omitted discussion of the choice of the final structural
model, with few exceptions (39). Such model choice largely
centers on the functional form of the exposure effect on the
Table 2. Effect of HAART on Incident AIDS or Death Among 950
Men and Women Infected With HIV Type 1, Multicenter AIDS Cohort
and Women’s Interagency HIV Studies, 1995–2007
Model Exposure Hazard Ratio 95% CLa
Unadjusted No ART 1
HAARTb 0.75 0.49, 1.17
Adjustedc 0.95 0.58, 1.56




Abbreviations: AIDS, acquired immunodeficiency syndrome; ART,
antiretroviral therapy; CL, confidence limits; HAART, highly active
antiretroviral therapy; HIV, human immunodeficiency virus.
a Robust for weighted models.
b Use during the prior 2 years.
c Controlled for time-varying prior CD4 cell count and HIV-1 RNA
level by using restricted cubic splines.
d Confidence limits obtained by the delta method using robust
variance.
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outcome, for which there is a broad literature. However,
a synthesis of that literature in the context of choice of the
final structural model is needed but is beyond the scope of
this paper. For instance, the choice of timescale to be used
affects the meaning of survival curves and may affect the
value of a summary hazard ratio. In addition, the choice of
how to represent exposure (e.g., 2-year window) may alter
results and have implications for clinical practice or public
policy.
The present results should be interpreted with consider-
ation of the following limitations. First, as is true of all
observational analyses, the estimates have a causal interpre-
tation only under the assumption of no unmeasured
confounding. This assumption likely holds approximately
here because the most important clinical and laboratory
information used by physicians as indications for HAART
was collected and used in the models to estimate the weights
(40). As described previously (30), numerous additional
functional forms for the weight models were explored
(e.g., longer covariate histories, more flexible splines), as
well as a broader set of covariates (e.g., age; race; body
mass index; HIV-related symptoms; Pneumocystis jiroveci
pneumonia prophylaxis therapy use; and red blood, platelet,
CD3, and CD8 cell counts), but such alternative model
specifications did not appreciably alter the results. If the
assumption of no unmeasured confounders is correct and
the model used to create the treatment weights is correctly
specified, then weighting creates a pseudo-population in
which the probability of HAART initiation is not a function
of the time-varying covariates (i.e., no confounding exists),
but the effect of HAART initiation on AIDS or death is the
same as in the actual study population.
Second, interpretable causal contrasts require that the
consistency assumption be met (41). The consistency
assumption is likely to hold approximately in the present
setting, where the exposure is a treatment (42, 43).
Third, valid use of IPTC weights requires that there not be
a probability of 0 or 1 that participants are exposed at any
level of the confounders among the uncensored (30). This
assumption was met in theory in our study and appeared to
be met in practice (notwithstanding wide-ranging predicted
probabilities of exposure) because some participants with
high CD4 counts and low viral load initiated HAART, while
others with low CD4 counts and high viral loads did not.
Refer to Cole and Hernán (30) for a more detailed discus-
sion of positivity in these data.
Fourth, and as in all prospective analyses with right
censoring, the results are based on the assumption that right
censoring is ignorable conditional on measured covariates.
Neither the present analyses nor past analyses (10, 27, 29,
44) suggest there is notable selection bias due to measured
variables in these data.
Fifth, the results rely on the assumption that time to AIDS
or death is measured without error. Moreover, we assume
that the semiannual data on covariates obtained from these
interval cohorts (45) are frequent enough so that the
information used by clinicians and participants to decide
on therapies is not overly coarsened. A prior report compar-
ing interval and clinical cohorts in HIV found similar
inferences (46). Furthermore, the calibrated results rely on
the assumption that the external validation data for HAART
use are accurate. Beyond the simple accuracy of reported
HAART use, there is the issue of transportability of the
validation data to the main study. The provided corrections
apply to the extent that the validation data proxy well for the
main study participants. Note that compatibility in partici-
pant characteristics is neither necessary nor sufficient for the
validation data to proxy well, but similarities in character-
istics, as found between our validation and main study data,
do provide some reassurance. Little prior work has been
published on how measurement error may affect results
from structural models for complex longitudinal data
(47, 48). For instance, random exposure measurement error
may not always lead to null bias because measured exposure
at time j may also act as a measured proxy for an unmea-
sured causal confounder for the effect of treatment at future
times (47), which would occur if the treatments Zij and Zijþ1
had an unmeasured common cause or treatment Zijþ1 was
determined in part by treatment Zij. In such cases, when the
IPTC weights account for the history of measured treatment
Xijþ1, we may not completely eliminate the confounding (in
either direction) by past actual treatment Zij.
One could account for measurement error in other ways.
For instance, with internal validation data, one could use
multiple imputation for measurement error correction
(49). Alternatively, one could use Bayesian or approximate
Bayesian (50, 51) methods with extensions to allow for
unidentified bias parameters (52). With any such misclassi-
fication correction method, an apparent loss of precision
with corrected estimates can be viewed as a movement of
the systematic error from a bias in the point estimate to
a less-biased estimate with increased uncertainty.
In conclusion, the observed association of HAART with
incident AIDS or death appears to persist for more than
a decade at a level stronger than observed using standard
statistical methods or marginal structural models assuming
no misclassification of reported HAART use. Without data
from fully compliant randomized trials that follow patients
with widely varying risk profiles for prolonged periods,
prospective observational studies with repeated assessments
of exposure and detailed collection of clinical and laboratory
information provide the best evidence available for estimat-
ing risk-group-specific, long-term therapeutic effects.
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APPENDIX 1
Validation Data
The mapping between the misclassified and true HAART
exposure is taken from 2 reports of validation data (53, 54).
In MACS, as reported by Cain (53), the validity of self-
reported use of HAART was assessed for 126 HIV-positive
adult men who were seen at least once during the period
from October 1, 2004, to April 1, 2008, at the Moore Clinic
in Baltimore; the Whitman Walker Clinic in Washington,
DC; or the Northwestern Clinic in Chicago. For each man,
the most recent single clinic visit that met the following
criteria was selected: it occurred between October 1,
2003, and April 1, 2008, with a subsequent MACS study
visit between October 1, 2004, and April 1, 2008, such that
the difference between clinic and study visits was less than 1
year (with a single exception of 1.16 years). In MACS (and
theWomen’s Interagency HIV Study), information on use of
each antiretroviral medication is elicited from the partici-
pant through interviewer-administered questionnaires with
the assistance of photo-medication cards. In the validation
substudy, data of all antiretroviral medications that the
participant was continuing or starting at the clinic visit were
abstracted. The MACS algorithm was used to classify each
participant’s drug combination as HAART or non-
HAART. When medical-record-abstracted HAART was
used as a ‘‘gold standard,’’ the numbers of true-positive,
true-negative, false-positive, and false-negative participants
were 101, 18, 4, and 3, respectively. Therefore, the sensitiv-
ity, specificity, and positive and negative predictive values of
self-reported HAART use were 97 (SE, 2), 82 (SE, 8),
96 (SE, 2), and 86 (SE, 8), respectively. This validation
sample of 126 men was aged 49 years (standard deviation,
8), and 55% were African American.
In the University of North Carolina Center for AIDS
Research HIV Cohort study, as reported by Brouwer et al.
(54), the validity of self-reported use of HAART was
assessed for a random sample of 205 HIV-infected adult
men and women who completed a 90-question clinical
and sociodemographic survey when seen between January
2001 and May 2006 at the University of North Carolina HIV
clinic in Chapel Hill. In the University of North Carolina
clinic cohort, each antiretroviral medication that the par-
ticipant was using at a clinic visit was abstracted from
medical records. In the validation substudy, partici-
pants were asked on the survey to report current use of
each antiretroviral medication. When medical-record-
abstracted therapies were used as a gold standard, a partic-
ipant using antiretroviral therapy who correctly reported
use of all antiretroviral therapies was considered a true
positive; conversely, a participant not using antiretroviral
therapy who correctly reported no use was considered
a true negative. During the calendar period during which
the study took place (i.e., 2001–2006), the vast majority of
HIV patients using antiretroviral therapies would have
been on a HAART regimen. The numbers of true-positive,
true-negative, false-positive, and false-negative partici-
pants were 103, 53, 14, and 35, respectively. Therefore,
the sensitivity, specificity, and positive and negative pre-
dictive values of self-reported therapy use were 75 (SE, 4),
79 (SE, 5), 88 (SE, 3), and 60 (SE, 5), respectively. This
validation sample of 205 participants was a median age of
42 years (quartiles: 36, 47), 66% male, and 71% African
American.
The pooled MACS and University of North Carolina data
yielded a sensitivity and specificity of 84 (SE, 2) and 80
(SE, 4), respectively. There was little heterogeneity in the
specificity between studies (chi-squared ¼ 0.08, P ¼ 0.78),
but there was notable heterogeneity in the sensitivities (chi-
squared ¼ 22.6, P < 0.01). Therefore, in addition to using
the pooled sensitivity and specificity, we present results
using the University of North Carolina and MACS valida-
tion data separately.
APPENDIX 2
Regression Calibration on IPTC Weighted Data
Regression calibration proceeds with an estimate of the
discrete-time log hazard ratio b̂1 between the misclassified
exposure and clinical AIDS or death, which is given by the
pooled logistic model described in the Statistical Methods
section of the text.
Second, a linear calibration model, EðZmjXmÞ ¼
c0 þ c1Xm, is fit to the pooled external validation data (refer
to Appendix 1), with random errors assumed em~Nð0;rÞ,
for m ¼ 1 to 331 (¼ 126 þ 205). Theoretical (55) and
simulation (17, 49) evidence supports the use of the
linear approximation with a misclassified dichotomous
exposure.
Third, a misclassification-corrected log hazard ratio is
obtained as ĥ1 ¼ b̂1=ĉ1, with 95% confidence limits for











1ÞV̂ðĉ1Þ, which is a first-order approximation using
the delta method but with a robust variance taken for the
discrete-time log hazard ratio.
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APPENDIX 3
Monte Carlo Simulation of Bias and Confidence Limit
Coverage
Data are simulated from the causal diagram (56, 57) il-
lustrated in Appendix Figure 1. Reading from Appendix
Figure 1, treatment has no direct causal effect on the time
to event. However, treatment at time 0, Z0, has an indirect
causal effect mediated through the time-varying covariate L.
Therefore, in this setting, the total causal effect equals the
indirect effect of initial treatment. Moreover, the time-vary-
ing covariate is a confounder of the association between
subsequent treatment Z1 and events, hence we
will subsequently refer to L as a time-varying confounder.
Treatment Zj is nondifferentially and independently misclas-
sified as Xj.
A simulated data record comprises a value for Z0, X0, L, Z1,
X1, T; we drew 1,000 simulated data records for each of
10,000 simulation data sets. First, a Bernoulli random
variable was generated with marginal probability P for treat-
ment at time 0, Z0. Second, a Bernoulli random variable was
generated with marginal probability 0.5 for the time-varying
confounder, L, conditional on the realized value of treatment
at time 0, z0, as 1=½1þ expða0 þ a1z0Þ. Third, a Bernoulli
random variable was generated with marginal probability
P for treatment at time 1, Z1, conditional on the realized value
of the time-varying confounder, ‘, as 1=½1þ expðb0 þ b1‘Þ.
Fourth, a Weibull random variable was generated conditional
on the realized value of the time-varying confounder ‘ with
shape parameter k ¼ expðc0  c1‘Þ and scale parameter j,
as jktj1expðktjÞ. The Weibull-distributed times were ad-
ministratively censored such that, in expectation, about 15%
of simulated subjects incurred events during follow-up.
Finally, X0 and X1 were generated such that there was a
sensitivity of 0.9 and specificity of 0.8. Calibration was
conducted with external validation sample size equal to the
study size.
We examined the scenario defined by P ¼ 1/2, j ¼ 2,
a1 ¼ log(5), b1 ¼ log(5), and c1 ¼ log(5), which we term
the alternative hypothesis scenario because the total causal
effect is nonnull (i.e., the expected causal hazard ratio is
1.7), and the scenario where a1 ¼ log(1), which we term
the null hypothesis scenario because the total causal effect
is null.
To compare the estimates, we calculated simulated bias,
computed as the estimated log hazard ratio minus the true
log hazard ratio; simulated standard error, computed as the
average of the estimated standard errors; and simulated
confidence limits coverage, computed as the proportion of
times that the confidence limits contain the true hazard ratio.
Simulation results are subject to Monte Carlo error; on the
basis of the 10,000 simulations, the 95% confidence limits
coverage estimates have a simulation standard error of ap-
proximately 0.2%.
For each of 10,000 simulation trials, we conducted 2
analyses estimating the association between cumulative
average treatment and time to event. First, we estimated
the association obtained from a standard marginal structural
Cox proportional hazards model, as detailed in the main text
as model 1. Second, we estimated the association obtained
from a marginal structural measurement-error Cox propor-
tional hazards model, as detailed in Appendix 2. Both
results were compared with the total causal effect obtained
as the indirect effect of initial treatment under the diagram
shown in Figure 1.
All simulations converged. Appendix Table 1 shows
that, under the alternative hypothesis, the standard
marginal structural model is null biased but the marginal
structural measurement-error model provides an unbiased
estimate of the total causal effect, as well as appropriate
confidence limits coverage, at a cost of reduced precision.
Under the null hypothesis, as expected, both the standard
and measurement-error models provided type 1 error rates
within 2 simulation standard errors of the expected 5%.
Appendix Table 1. Simulated Bias, Robust Standard Error, and
Confidence Limit Coverage for Standard Marginal Structural and
Marginal Structural Measurement-Error Cox Models Under an
Alternative and Null Hypothesis and Nondifferential and Independent











Standard 0.162 (0.002) 0.213 (0.001) 88.4 (0.3)
Measurement
error
0.003 (0.003) 0.296 (0.001) 95.2 (0.2)
Null hypothesis
Standard 0.001 (0.002) 0.215 (0.001) 4.6 (0.2)
Measurement
error
0.001 (0.003) 0.292 (0.001) 5.4 (0.2)
Abbreviations: CL, confidence limits; MCSE, Monte Carlo simula-
tion error; SE, standard error.
a Type 1 error rate under null hypothesis.
Appendix Figure 1. Causal diagram depicting simulation data. T is
time to acquired immunodeficiency syndrome or death, Zj is the true
exposure to highly active antiretroviral therapy for j ¼ f0,1g, Xj is the
measured exposure to highly active antiretroviral therapy, L are
the time-varying confounders, and U are unmeasured determinants
of the subscripted variable.
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